Table 1.
Biological properties of the selected MDM2 inhibitors with demonstrated effect on anti-tumor immune response.
| Molecule name | Chemical structure | Key features | Cancer type in vitro and/or in vivo studies |
Immune function |
|---|---|---|---|---|
| Navtemadlin (KRT-232, AMG-232) |  |
Piperidinone | NSCLC, Merkel Cell Carcinoma， Ovarian Clear Cell Carcinoma |
T cell activation ↑ |
| Siremadlin (HDM-201) |  |
Pyrrolidonoimidazole scaffold | Colon Cancer, Melanoma | DC proliferation ↑ T cell activation ↑ MHC expression ↑ NK cell apoptosis↓ |
| Alrizomadlin (APG-115) |  |
Spirooxindole based | Melanoma, MPNST, NSCLC, Solid Tumors, Well Differentiated/Dedifferentiated Liposarcoma |
M1-Macrophage polarization↑ PD-L1 expression↑ |
| Nutlin3 |  |
Cisimidazoline analogues | Lymphoma, Melanoma |
DC and macrophage proliferation↑ T cell activation ↑ PD-L1 expression↑ |
| RG7112 |  |
Cisimidazoline derivative | Melanoma | T cell activation↑ MHC expression↑ |